MRK’s HCV combo (MK-5172+MK-8742) receives FDA Breakthrough Therapy designation: http://finance.yahoo.com/news/merck-receives-breakthrough-therapy-designation-210000104.html ABBV/ENTA’s HCV combo (ABT-450 + ABT-267 + ABT-333) already has such a designation.